Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.

ABSTRACT:

Importance

Obesity has become a global public health concern and China has the largest number of affected people worldwide.

Objective

To assess the efficacy and safety of treatment with tirzepatide for weight reduction in Chinese adults with obesity or overweight and weight-related comorbidities.

Design, setting, and participants

This randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 29 centers in China from September 2021 to December 2022 included Chinese adults (aged ≥18 years) with a body mass index (BMI) greater than or equal to 28 or greater than or equal to 24 and at least 1 weight-related comorbidity, excluding diabetes.

Interventions

Participants were randomly assigned (1:1:1) to receive once-weekly, subcutaneous 10-mg (n

SUBMITTER: Zhao L 

PROVIDER: S-EPMC11337071 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature